2009/12/20 by Matthew P. Kosloski, Haoyu Wang, David Pugatch +17
Medicine · #Cytomegalovirus and herpesvirus research #HIV/AIDS drug development and treatment #Hepatitis C virus research #Silymarin and Mushroom Poisoning #Systemic Lupus Erythematosus Research
paper · doi:10.1007/s00228-018-2576-4
openalex publication_date 2009/12/20 · openalex created_date 2016/06/24 · crossref issued 2018/10/19 · crossref published 2018/10/19 · crossref published-online 2018/10/19 · crossref created 2018/10/19 · crossref published-print 2019/02/01 · crossref deposited 2019/10/18 · openalex updated_date 2026/06/11 · crossref indexed 2026/07/30
This study supported evaluation of the glecaprevir 300 mg with pibrentasvir 120-mg combination in HCV-infected subjects with CP-A hepatic impairment without dose adjustment. Elevated glecaprevir and/or pibrentasvir exposures are expected in HCV-infected patients with CP-B or CP-C hepatic impairment.